EWTX vs. KURA, ZGNX, ANAB, XENT, PTCT, ELAN, KRYS, OGN, NUVL, and BBIO
Should you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Kura Oncology (KURA), Zogenix (ZGNX), AnaptysBio (ANAB), Intersect ENT (XENT), PTC Therapeutics (PTCT), Elanco Animal Health (ELAN), Krystal Biotech (KRYS), Organon & Co. (OGN), Nuvalent (NUVL), and BridgeBio Pharma (BBIO). These companies are all part of the "medical" sector.
Kura Oncology (NASDAQ:KURA) and Edgewise Therapeutics (NASDAQ:EWTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Kura Oncology's return on equity of -29.09% beat Edgewise Therapeutics' return on equity.
Kura Oncology received 380 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. Likewise, 69.11% of users gave Kura Oncology an outperform vote while only 67.57% of users gave Edgewise Therapeutics an outperform vote.
Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Kura Oncology has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, Edgewise Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.
In the previous week, Edgewise Therapeutics had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Edgewise Therapeutics and 3 mentions for Kura Oncology. Edgewise Therapeutics' average media sentiment score of 1.24 beat Kura Oncology's score of 0.62 indicating that Kura Oncology is being referred to more favorably in the media.
Kura Oncology currently has a consensus target price of $31.33, indicating a potential upside of 48.57%. Edgewise Therapeutics has a consensus target price of $33.20, indicating a potential upside of 74.92%. Given Kura Oncology's higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Kura Oncology.
Summary
Kura Oncology and Edgewise Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.
Get Edgewise Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edgewise Therapeutics Competitors List
Related Companies and Tools
Free EWTX Stock Alerts